Portfolio of Gene Editing (CRISPR) Stocks

Here are 4 gene editing stocks that use CRISPR technology.

4 Portfolio of Gene Editing (CRISPR) Stocks

Stock & Price Chart


Recent Prices &
Annualized Return

Crispr TherapeuticsCRSP
Editas MedicineEDIT
Intellia TherapeuticsNTLA
Vertex PharmaceuticalsVRTX
Price data from Quandl as of most recent close.

To inspect the performance of the Portfolio of Gene Editing (CRISPR) Stocks portfolio, see the chart of portfolio below. Portfolio values are computed using monthly closes for stocks from Quandl.

All 4 stocks are included in the portfolio computations. The current value of the portfolio assumes that $2,500.00 was invested (total of $10,000) in each stock at its closing monthly price for the current date in 2017. All prices are adjusted for splits and dividends.

The current value of a $10,000 investment is $16,658. The percent return is 66.58%. The annualized return is 24.45%.

NOTE: The stocks included in the table and chart are representative of the industry. They are not recommendations.

Related Portfolios

Portfolio of Biotech Stocks

Portfolio of Genetic Testing Stocks

Portfolio of Genomics Stocks

Portfolio of Stem Cell Stocks